Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Business Wire•14/10/2026•07:00 ET
0
Key Highlights
- ➤Zai Lab (ZLAB) will present first clinical ZL-1503 data at ACAAI 2026
- ➤Phase 1/1b healthy-volunteer data include pharmacokinetics, biomarkers, safety, and immunogenicity
- ➤ZL-1503 targets IL-13 and IL-31Rα for atopic dermatitis and related diseases
- ➤Investor call and webcast scheduled November 13 at 8:00 a.m. ET
Expert Statements
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“Atopic dermatitis and other IL-13- and IL-31-driven diseases can severely impact patients’ health and quality of life”
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“Preclinically, ZL-1503 has shown the potential to provide relief of pruritus and inflammation in atopic diseases with less frequent dosing than other biologic therapies.”
Rafael G. Amado, President, Head of Global Research and Development at Zai Lab
“We look forward to sharing results from the healthy volunteers’ study cohort evaluating this bispecific antibody with the immunology community at ACAAI.”
Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting
Get started
Create a free account to read the full story.